The London-based investment group, Arix Bioscience Plc, has co-led a $63 million investment round in Imara Inc, a US company developing a small molecule drug to treat sickle cell disease, a rare genetic blood disorder that can lead to organ injury. Joining Arix as co-leader of the Series B round was Orbimed Advisors.
